Melanoma Institute Australia shines at prestigious Cancer Research Awards
3 November 2018
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
Professor Georgina Long, Co-Medical Director of Melanoma Institute Australia, has won the top award for Outstanding Cancer Researcher of the Year. One of the world’s pre-eminent melanoma clinicians and researchers, Professor Long has changed the face of melanoma treatment around the world with her ground-breaking clinical trials tripling life expectancy for patients with advanced melanoma and curing a significant subset.
Fellow MIA Co-Medical Director, Professor Richard Scolyer, has been awarded The Professor Rob Sutherland AO Make a Difference Award, which is awarded in recognition of lasting impact and sustained progress to cancer care or research practice. Professor Scolyer is the world’s leading melanoma pathologist, each year receiving more than 2,000 cases for review and opinion from around the world. He recently co-edited the new WHO Classification of Skin Tumours, 4th Edition.
Also awarded were MIA’s Associate Professor Alex Menzies, who won the Outstanding Cancer Research Fellow Award with less than five years post-doctoral experience in research, and Associate Professor Anne Cust, who was awarded Outstanding Cancer Research Fellow with more than five years post-doctoral experience in research.
Associate Professor Menzies is a Medical Oncologist with research interest in clinical trials of new systemic therapies for melanoma, biomarkers of response and resistance to systemic therapy, and immunotherapy-related toxicity. Associate Professor Cust is an epidemiologist whose research focuses on melanoma epidemiology, prevention, early detection and survivorship and has a strong emphasis on translational outcomes.
Melanoma Institute Australia CEO Matthew Browne said it was a proud moment to see Melanoma Institute Australia’s research and clinical team centre stage at the prestigious awards night.
‘This is well deserved recognition for not only these award winners, but also the multi-disciplinary teams across MIA that work tirelessly to develop new treatments to save lives from melanoma,’ Mr Browne said.
‘My particular congratulations go to Professor Long for taking out the prestigious Outstanding Cancer Researcher of the Year Award. This is testament to her research and global thought leadership which has set the world on the path towards advanced melanoma becoming a chronic disease rather than a terminal one.
‘She was gracious in acknowledging the award was recognition of the whole team’s efforts at MIA, and particularly her long research partnership with Professor Richard Scolyer.
‘With the breakthroughs in melanoma treatment also set to revolutionise treatments for other cancers, Professor Long’s legacy will potentially impact millions across the globe.’
Major award for world-leaders in melanoma research
Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.
Melanoma Institute Australia shines at prestigious Cancer Research Awards
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
Women of MIA lead the way in melanoma research at SMR
An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.
Immune cell research presented at SMR
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.
Patients to benefit from updated skin tumour publications
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
SunSafe Student Ambassador Program
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
International collaboration the key to increasing survival
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
High-risk Stage III melanoma patients to benefit from Australia/Netherlands collaboration
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
Monthly dose of immunotherapy allows flexibility for patients undergoing treatment
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
Australia's best minds in melanoma research converge on Melbourne
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
Nobel Prize for novel cancer therapies
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
World Health Organisation launches 4th edition of Classification of Skin Tumours
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Professor John Thompson awarded prestigious 2018 RPA Foundation Research Medal
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Support PBS listing for pembrolizumab
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
World Congress on Cancers of the Skin 2018
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia welcomes new CEO Matthew Browne
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
Melanoma in Practice: Nurse Conference
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
Reducing the risk of melanoma in young adults
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia launches free e-learning education portal
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.